Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLAMF7 FPBMC in Relapsed/Refractory Multiple Myeloma
NCT04864522Phase 2Withdrawn
- Sponsor
- University of Virginia
- Start
- Aug 2023
- Primary completion
- Nov 2023
- Modality
- Bispecific Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of SLAMF7 FPBMC in multiple myeloma (MM), sponsored by University of Virginia. Planned start Aug 2023; status: withdrawn.
02
Drugs
SLAMF7 FPBMC
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04864522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04864522.